Novartis (NYSE:NVS) has decided to stop development of fevipiprant after a series of unsuccessful clinical trials. In October, the DP2 antagonist failed improve lung function in two Phase 3 studies in patients with moderate asthma.
Two additional trials, in patients with moderate-to-severe asthma, also came up empty.
At its R&D Day on December 6, the company listed the drug as one of its key filings for 2020.
Related ticker: Gossamer Bio (NASDAQ:GOSS) (lead drug is GB001, also a DP2 antagonist).
Try Seeking Alpha PREMIUM for unlimited analysis on NVS